Since 2010, Medio-Haus has manufactured Avedro’s proprietary VibeX riboflavin products and will now also provide all of its MedioCROSS riboflavin products exclusively through Avedro. Avedro’s family of riboflavin products are used with Avedro’s KXL® System for performing Lasik Xtra® as well as accelerated cross-linking for treating keratoconus and post-LASIK ectasia outside the United States.
The MedioCROSS riboflavin products are currently used with a variety of cross-linking devices to treat keratoconus and post-LASIK ectasia and had previously been supplied to distributors through Peschke-Meditrade, an ophthalmic products supply company. Avedro will continue to offer the full line of Medio-Haus riboflavin products to prevent any interruption of supply to the current customers of those products located outside of the United States. In the coming weeks, Avedro will reach out to ophthalmologists that use MedioCROSS products and the distributors currently selling to them to ensure a continued supply.
David Muller, PhD, CEO of Avedro commented, “I am extremely pleased to have consummated this important transaction with Medio-Haus. Under the direction of its founder, Thomas Steffens, Medio-Haus has emerged as the highest quality manufacturer of ophthalmic riboflavin products in the world. With this agreement Avedro has strengthened its market position in the distribution of riboflavin products worldwide. We look forward to expanding our customer base and supplying the former Peschke Meditrade customers with the same premium level of service that our current customers now enjoy.”
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking and refractive correction. Avedro’s products include capital equipment and related single dose pharmaceuticals.
Avedro distributes its products in 62 countries through 33 ophthalmic distributors with 115 sales and service representatives. Avedro products that have received CE Mark include: the KXL System for performing Lasik Xtra and accelerated cross-linking , the KXL II™ System for performing PiXL™ , and the Avedro family of proprietary single dose pharmaceutical formulations. Avedro’s KXL System and single dose pharmaceutical products are currently being used in three Phase III US clinical trials involving over 100 US clinical sites. Avedro products are not for sale in the US.
SOURCE: Avedro Inc.